Company: PTPI
Filing Date: 2025-02-14
Form Type: S-1/A
Source: 0001410578-25-000137
Chunk: 17

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-14
Form: S-1/A
Chunk 17
---
 information. |

| ● | Petros’ business will expose it to potential liability for the quality and safety of its products and services, how it advertises and markets those products and services and how and to whom it sells them, and Petros may incur substantial expenses or be found liable for substantial damages or penalties if it is subject to claims or litigation. |

| ● | The Vivus Event of Default constitutes a Triggering Event (as defined in the Certificate of Designations) pursuant to the terms of the Certificate of Designations, which may materially and adversely affect our liquidity, financial condition and results of operations. |

6

| ● | Changes in laws could negatively impact Petros’ business. |

| ● | The regulatory framework for artificial intelligence (“AI”) technologies is rapidly evolving as many federal, state and foreign government bodies and agencies have introduced or are currently considering additional laws and regulations. In addition, existing laws and regulations may be interpreted in ways that would affect the use of AI in Petros’ business. As a result, implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and Petros cannot yet determine the impact future laws, regulations, standards, or market perception of their requirements may have on its business and may not always be able to anticipate how to respond to these laws or regulations. |

| ● | If Petros fails to protect its intellectual property rights, its ability to pursue the development of its products would be negatively affected. |

| ● | Changes in trends in the pharmaceutical and medical device industries, including changes to market conditions, could adversely affect Petros’ operating results. |

| ● | Acquisitions involve risks that could result in a reduction of our operating results, cash flows and liquidity. |

| ● | Holders of Petros’ Series A Preferred Stock are entitled to certain payments under the Certificate of Designations that may be paid in cash or in shares of common stock depending on the circumstances. If Petros makes these payments in cash, it may be required to expend a substantial portion of its cash resources. If Petros make these payments in common stock, it may result in substantial dilution to the holders of common stock. |

| ● | The Certificate of Designations for the Series A Preferred Stock and the warrants issued concurrently therewith contain anti-dilution provisions that may result in the reduction of the conversion price of the Series A Preferred Stock or the exercise price of such warrants as a result of this offering and in the future. These features may increase the number of shares of common stock being